The Delaware Court of Chancery appears positioned to once again decide whether to keep afloat a once-promising multibillion-dollar merger that has since struck the rocks in a pair of dueling breach of contract lawsuits.
Since Abbott Laboratories agreed in January to buy Alere for $5.8 billion, the Massachusetts-based medical testing company has delayed its annual financial reporting and disclosed that it is facing three investigations by the U.S. Department of Justice into its Medicaid billing, the integrity of a product line and its overseas sales practices.
